L26/O-236 Liability for experimental ART innovations: determining responsibility between clinicians, institutions, and device manufacturers under evolving treatment standards
Human Reproduction · 01.07.2026 · 41 (Supplement_1)
DOI: 10.1093/humrep/deag083.234 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von S. Tom.
Abstract (Originalsprache)
Study question How do courts determine liability when experimental ART techniques cause harm, and what standard of care applies to innovative treatments? Summary answer Courts apply modified Bolam principles emphasising informed consent disclosure; liability increasingly extends to device manufacturers under product liability frameworks. What is known already ART innovation includes novel culture media, time-lapse imaging, endometrial scratching, and emerging techniques. Clinical negligence claims require duty of care, breach of the duty of care, causation, and injury/loss. The Bolam test assesses breach via professional opinion, but Montgomery v Lanarkshire refined informed consent requirements, emphasising material risk disclosure. Experimental treatment cases (e.g., Simms v Simms) permit innovation where potential benefit exists and consent obtained. Product liability under Consumer Protection Act 1987 creates strict liability for defective products. Existing case law addresses obstetric negligence but limited ART-specific innovation liability precedent exists. Causation challenges arise when techniques lack long-term outcome data. Study design, size, duration Systematic case law analysis and doctrinal legal review examining clinical negligence principles, informed consent requirements, and product liability frameworks applicable to ART innovations. Participants/materials, setting, methods Review of reported judgments involving experimental ART techniques, novel devices, or off-label medication use. Doctrinal analysis of negligence principles, informed consent requirements under Montgomery, and product liability frameworks under Consumer Protection Act 1987. Main results and the role of chance Courts consistently apply Montgomery disclosure standards to experimental ART techniques; inadequate disclosure of experimental nature constitutes negligence where material risks are undisclosed. Bolam remains applicable to technique execution; breach established where no responsible body of professional opinion supports innovation under circumstances. Causation presents significant challenges due to background ART failure rates and difficulty attributing harm to specific innovations versus underlying infertility or chance. Product liability claims increasingly relevant as ART incorporates medical devices, culture media, and cryopreservation systems. Strict liability under Consumer Protection Act 1987 enables recovery without proving clinical negligence; “defect” interpretation applies consumer expectation and risk-benefit tests. Institutional liability arises vicariously for clinician negligence and directly for inadequate governance, oversight, or approval of experimental techniques. Informed consent documentation critical to defending claims; detailed consent forms documenting experimental status, alternative options, outcome uncertainty, and material risks provide substantial protection. Simms v Simms [2002] principles permit innovative treatment where potential benefit exists, no standard treatment available, and informed consent obtained. Limitations, reasons for caution Published case law represents litigated disputes; settlement outcomes lack reasoned judgments. Product liability jurisprudence continues developing. Long-term harm from recent innovations may not yet manifest. Wider implications of the findings Comprehensive informed consent processes essential for innovation protection. Product liability framework increasingly relevant as ART technologies advance. Institutional governance mechanisms require robust oversight. Trial registration number No
Zitieren
APA
Tom, S. (2026). L26/O-236 Liability for experimental ART innovations: determining responsibility between clinicians, institutions, and device manufacturers under evolving treatment standards. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.234
Vancouver
Tom S. L26/O-236 Liability for experimental ART innovations: determining responsibility between clinicians, institutions, and device manufacturers under evolving treatment standards. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.234
BibTeX
@article{Tom2026,
author = {Tom, S.},
title = {L26/O-236 Liability for experimental ART innovations: determining responsibility between clinicians, institutions, and device manufacturers under evolving treatment standards},
journal = {Human Reproduction},
year = {2026},
volume = {41},
number = {Supplement_1},
doi = {10.1093/humrep/deag083.234}
}
EUVIMED